Table 5 The prognostic factors for unconventional metastatic patients in the RRG group
Variables | The overall survival rate | P value | |
|---|---|---|---|
Univariate analysis | Cox modelb | ||
Age | 0.500 | NA | |
33–59(25) | 16.0% | ||
60–87(11) | 9.1% | ||
Gender | 0.286 | NA | |
Male(24) | 12.5% | ||
Female(12) | 16.7% | ||
Histories of smoking and alcohol | 10.0% | 0.248 | NA |
Yes(20) | 10.0% | ||
No(16) | 12.5% | ||
Premalignant mucosal diseases | 0.484 | NA | |
Yes(8) | 12.5% | ||
No(28) | 14.3% | ||
Prior radio- or chemo-therapies | 0.809 | NA | |
Yes(21) | 19.0% | ||
No(15) | 6.7% | ||
Primary site | 0.838 | NA | |
Buccal mucosa(5) | 40.0% | ||
Upper gingiva(7) | 14.3% | ||
Lower gingiva(5) | 20.0% | ||
Floor of mouth(3) | 33.3% | ||
Retromolar trigone(8) | None | ||
Tongue(7) | None | ||
Hard palate(1) | None | ||
Unconventional metastatic subsites | 0.122 | NA | |
Buccinator (16) | 18.8% | ||
Sublingual(11) | 9.1% | ||
Parotida(9) | 11.1% | ||
Pathological grade | 0.172 | NA | |
II(19) | 26.3% | ||
III(17) | None | ||
Pathological grade is upgraded compared to the last surgery | 0.404 | NA | |
Yes(16) | 6.3% | ||
No(20) | 20.0% | ||
Number of metastatic lymph nodes in the unconventional subsites | 0.617 | NA | |
1(29) | 13.8% | ||
2(6) | 16.7% | ||
3(1) | None | ||
Lymph nodes size of UMLNs | 0.808 | NA | |
0–3 cm(22) | 9.1% | ||
> 3 cm(14) | 21.4% | ||
Last neck dissections | 0.407 | NA | |
ISND(13) | 7.7% | ||
IRND(12) | 25.0% | ||
BND(1) | None | ||
No treatment(10) | 10.0% | ||
Neck dissections this time | 0.426 | NA | |
ISND(5) | 20.0% | ||
IRND(7) | 14.3% | ||
CND(8) | None | ||
BND(9) | None | ||
No treatment(7) | 42.9% | ||
Extranodal extension (ENE) in UMLNs | 0.290 | NA | |
Yes(16) | 18.8% | ||
No(20) | 10.0% | ||
Contralateral metastasis | 0.124 | NA | |
Yes(13) | None | ||
No(23) | 21.7% | ||
Cervical lymph node metastasis | 0.066 | NA | |
Yes(22) | None | ||
No(14) | 35.7% | ||
Extranodal extension (ENE) in cervical lymph nodes | 0.030 | 0.030 | |
Yes(10) | None | ||
No(26) | 19.2% | ||
Postoperative adjuvant therapies | 0.719 | NA | |
Radiotherapy(13) | 15.4% | ||
Chemotherapy(3) | None | ||
Radio-chemotherapies(8) | 12.5% | ||
None(12) | 16.7% | ||